Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) FCF Margin (2016 - 2025)

Adma Biologics' FCF Margin history spans 13 years, with the latest figure at 24.83% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1554.0% year-over-year to 24.83%; the TTM value through Dec 2025 reached 5.45%, down 2045.0%, while the annual FY2025 figure was 5.45%, 2045.0% down from the prior year.
  • FCF Margin reached 24.83% in Q4 2025 per ADMA's latest filing, up from 0.8% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 40.66% in Q2 2024 to a low of 223.07% in Q1 2021.
  • Average FCF Margin over 5 years is 32.71%, with a median of 16.38% recorded in 2023.
  • Peak YoY movement for FCF Margin: soared 18912bps in 2021, then plummeted -2531bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 67.53% in 2021, then soared by 67bps to 22.26% in 2022, then surged by 200bps to 22.19% in 2023, then surged by 82bps to 40.37% in 2024, then crashed by -38bps to 24.83% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's FCF Margin are 24.83% (Q4 2025), 0.8% (Q3 2025), and 15.34% (Q2 2025).